Weir Kristie Rebecca (Orcid ID: 0000-0002-9507-5050)

Older adults' adherence to medications and willingness to deprescribe: A sub-study of a randomized clinical trial

Short running title: Adherence to medications and willingness to deprescribe

Author list

Kristie Rebecca Weir *(shared first author)*

Institute of Primary Health Care BIHAM, University of Bern, Bern, Switzerland

Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, Australia

kristie.weir@sydney.edu.au

Katharina Tabea Jungo *(shared first author)*

Institute of Primary Health Care BIHAM, University of Bern, Bern, Switzerland

Center for Healthcare Delivery Sciences, Brigham and Women's Hospital, Boston, MADivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

katharina.jungo@unibe.ch

Sven Streit (PI)

Institute of Primary Health Care BIHAM, University of Bern, Bern, Switzerland

sven.streit@unibe.ch

Article type

Short communication

Word count: 1,888

Data availability statement

We will make the data for this study available to other researchers upon request after publication. The data will be made available for scientific research purposes, after the proposed analysis plan has been approved. Data and documentation will be made available through a secure file exchange platform after approval of the proposal. In addition, a data transfer agreement must be signed (which defines obligations that the data requester must adhere to with regard to privacy and data handling). Deidentified participant data limited to the data used for the proposed project will be made available, along with a data dictionary and annotated case report forms. For data access, please contact the corresponding author.

Ethics approval statement

The study protocol of the OPTICA trial and other documentation was approved by the competent ethics committee of the canton of Bern (KEK), Switzerland, and the Swiss regulatory authority (Swissmedic) (BASEC ID: 2018–00914). The KEK and Swissmedic received annually safety reports and were informed about the end of the study.

Patient consent statement

All participants gave their written informed consent. The OPTICA trial was performed in accordance with relevant regulations and guidelines.

Scholarship, a Swiss National Science Foundation Scientific Exchanges grant and a NHMRC Emerging Leader Research Fellowship (2017295).

Conflict of interest disclosure

The authors do not have any conflicts of interest to disclose.

Acknowledgements

Author contributions

All authors contributed to the concept and study design. All authors contributed to the acquisition, analysis, or interpretation of data. KTJ and KRW wrote the first draft of the manuscript. All other authors provided feedback and approved the final version of the manuscript. KTJ and SS provided administrative and technical support. KTJ did the statistical analyses. SS obtained funding for the work and supervised the study. KTJ and KRW had full access to all the data in the study and are the guarantors.

Abbreviations

OPTICA, Optimizing PharmacoTherapy In the Multimorbid Elderly in Primary CAre trial

rPATD, revised Patient Attitudes Towards Deprescribing' questionnaire

eCDSS, electronic clinical decision support system

STRIP-Assistant, Systematic Tool to Reduce Inappropriate Prescribing-Assistant

MAI, Medication Appropriateness Index

AOU, Assessment of Underutilization

IQR, interquartile range

What is already known about this subject

- Medication-related problems, high treatment burden, and polypharmacy can lead to reduced adherence to medications, and they can be triggers for deprescribing – dose reduction or discontinuation of selected medicines.

- The interplay between deprescribing and medication adherence is influenced by patient-related factors such as attitudes, beliefs, perceived necessity, and concerns about medications.

- Understanding patients' willingness to deprescribe or adhere to their medications is crucial for collaborative decision-making in the context of polypharmacy.

What this study adds

- Our study examined the association between patients' reported willingness to have medications deprescribed and medication adherence in older adults with multimorbidity and polypharmacy.

- The longitudinal study design allowed for a clear temporal distinction between patients' willingness to have medications deprescribed assessed at baseline and medication adherence at 12-month follow-up.

- Participants reported a high level of medication adherence and willingness to have medications deprescribed, however, we did not find any evidence for an association between willingness to deprescribe and adherence.

Abstract

Our study investigated the association between patients' willingness to have medications deprescribed and medication adherence. This longitudinal sub-study of the 'Optimizing PharmacoTherapy In the Multimorbid Elderly in Primary CAre' (OPTICA) trial, a cluster randomized controlled trial, took place in Swiss primary care settings. Participants were aged ≥65 years and over, with ≥3 chronic conditions, and ≥5 regular medications. At baseline the 'revised Patient Attitudes Towards Deprescribing' (rPATD) questionnaire was measured. The A14-scale measured adherence (self-report) at the 12-month follow-up. Multilevel linear regression analyses adjusted for baseline variables were performed. Of the 298 participants, 45% were women and the median age was 78. Participants reported a high level of adherence and willingness to have medications deprescribed. We did not find evidence for an association between patients' willingness to deprescribe and medication adherence. Further research is needed to explore the relationship between these concepts and to inform collaborative decisions about medicines in the context of polypharmacy.

Introduction

Many older adults aged ≥65 years take at least one potentially inappropriate medication daily.[1,2] Recent international data from five European countries found that 45% of older adults report engaging in polypharmacy (taking five or more medications daily) and 42% had a high risk of experiencing medication-related problems.[3] High treatment burden, medication-related problems and polypharmacy can lead to reduced adherence[4,5] or they can be cause for deprescribing – a process of dose reduction or discontinuing selected medicines.[6] Of note, reduced adherence to medication is an important opportunity and reason for deprescribing identified by European geriatricians.[7]

Adherence to medications is less common than it appears with a recent German study finding that only a quarter of participants in a representative sample described themselves as being fully adherent to their medication regimen.[8] The definitions and measures of adherence vary, however, discontinuing a medication earlier than recommended is an aspect of adherence that relates to deprescribing.[9] A national poll of American adults about deprescribing found that of those who had stopped taking a medication (without a replacement), 36% did so *without* talking to a healthcare professional.[10] Depending on how this is viewed, it could be considered an opportunity for retrospective deprescribing or medication non-adherence. On the other hand, clinicians say deprescribing is a complex process and can be challenging to implement because older patients are often hesitant to stop their medications.[11]

A person's beliefs and attitudes towards their medications play a key role in how willing they are to start, continue or stop taking a medication.[12] Adherence and deprescribing are both influenced by the following patient-related factors about medications: positive or negative attitudes, beliefs about the potential impact, perceived necessity and importance, and fears or concerns about the medication and/or the health condition.[13]

It is important to better understand the association between willingness to deprescribe and medication adherence, as this is key to understanding patient attitudes, priorities, and preferences in the context of polypharmacy. From here, shared decisions about medicines and attempts to optimize medication use can be made. However, the complex interplay

between deprescribing and medication adherence has not been fully explored in the literature. Our study contributes to the literature by investigating the association between patients' willingness to have medications deprescribed and medication adherence in a sample of older adults with multimorbidity and polypharmacy.

Methods

Overview of the OPTICA trial

The methods and results of the "Optimising PharmacoTherapy In the multimorbid elderly in primary Care" (OPTICA) trial (*clinicaltrials.gov identifier: NCT03724539*) have been reported elsewhere.[17-20] From January 2019 to February 2020 a total of 323 patients from 43 GP practices were recruited into this cluster randomized clinical trial. The last patient completed the 12-month follow-up in February 2021. In the OPTICA trial, 21 GPs with 160 patients were assigned to the intervention group and 22 GPs with 163 patients to the control group. Eligible patients were older adults with multiple chronic conditions and regularly using several medications. While GPs in the control group continued to provide usual care to their patients, GPs in the intervention group performed a structured medication review centred around an electronic clinical decision support system (eCDSS) called the "Systematic Tool to Reduce Inappropriate Prescribing"-Assistant (STRIP-Assistant). This eCDSS is based on the STOPP/START criteria and generated prescribing recommendations to stop, start, or adapt the dosage and flagged interactions.[21-23]

Due to the pragmatic design, data for the OPTICA trial was partly collected from participants' electronic health records (e.g., medications, diagnoses) and partly from participants or their legal representatives over the phone (e.g., quality of life, medication adherence, willingness to deprescribe, sociodemographic characteristics). The two primary outcomes of the trial were the improvement in the Medication Appropriateness Index (MAI) and the Assessment of Underutilization (AOU) at 12 months. Secondary outcomes included the number of medications, number of falls, fractures, and quality of life. The results of the trial on whether

the medication review intervention led to an improvement in outcomes were inconclusive. The OPTICA trial was approved by the competent cantonal ethics committee (*BASEC-ID: 2018–00914*). All participants or their legal representatives provided written informed consent.

Study design and Sample Definition

This is a longitudinal sub-study of the OPTICA trial. Data from the trial baseline and the 12-month follow-up were used for the analyses. This manuscript adheres to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for observational studies.[24] All 323 participants of the OPTICA trial were older adults (≥65 years of age), with multimorbidity (≥3 chronic conditions) and polypharmacy (≥5 medications). The present analyses were limited to the participants for whom the patient version of the 'revised Patient Attitudes Towards Deprescribing' (rPATD)[25] questionnaire was assessed at baseline.

Assessment of patients' willingness to have medications deprescribed

Patients' attitudes towards having medications deprescribed was measured using the rPATD[25] at baseline (**Box 1**). Several rPATD questions were chosen as independent variables to measure the variation in patients' self-reported attitudes towards deprescribing, rather than the global question alone which tends to have a ceiling effect.[26] The variables were dichotomized creating a category with patients reporting to be agreeing or strongly agreeing with the rPATD statements, and another group with patients reporting to be unsure, disagreeing or strongly disagreeing. This approach was chosen because there were very few events in some of the categories of the original 5-point Likert scale.

Box 1: Independent variables: rPATD[25] questions about attitudes towards deprescribing

Global question:
"If my doctor said it was possible, I would be willing to stop one or more of my regular medicines"
Appropriateness questions:
"I would like to try stopping one of my medicines to see how I feel without it"
"I would like my doctor to reduce the dose of one or more of my medicines"
Concerns about stopping questions score, ranging from 1 to 5, calculated based on the following rPATD questions:
"I have had a bad experience when stopping a medicine before"
"I would be reluctant to stop a medicine that I had been taking for a long time"
"If one of my medicines was stopped I would be worried about missing out on future benefits"
"I get stressed whenever changes are made to my medicines"
"If my doctor recommended stopping a medicine I would feel that he/she was giving up on me"
Response items (Likert-scale):
Strongly agree, agree, unsure, disagree and strongly disagree

Assessment of medication adherence

The A14-scale[27] was used to measure patients' medication adherence and individual barriers to adherence. This questionnaire contains 14 Likert-scale questions ranging from "never" (4 points) to "very often" (0 points). The total score ranges from 0 to 56 where a higher score represents better adherence. The score was used as a continuous outcome in our analyses and medication adherence was assessed at the 12-month follow-up.

Statistical analyses

First, the demographics and main clinical characteristics of study participants were described, by willingness to have medications deprescribed. Second, patients' baseline willingness to have medications deprescribed was described. Third, then multilevel linear regression analyses were performed using a two-stage approach with a minimally and a fully adjusted model. All models were adjusted for the clustering effect at the level of general practitioner, the group allocation, and a selection of covariates. The fully adjusted model was adjusted for the following covariates: patient age, gender, educational status, living situation, number of

chronic conditions, number of chronic medications, informal care received (yes/no), number of GP visits, number of specialist visits, number of hospitalizations, and proxies for patient satisfaction with and financial burden caused by medication use (measured with rPATD questions "I spend a lot of money on my medicines" and "Overall, I am satisfied with my current medicines"). Financial burden and satisfaction with medication use can be important factors influencing patients' medication-related decisions.[28-30] Including them in the model allows to control for potential confounding. The minimally adjusted model was adjusted for the following covariates: patient age and gender.

Results

Table 1 shows participants' baseline characteristics by medication adherence. 45% of participants in the sample were women (n=133) and median age was 78 (interquartile range: 74-83). Most participants reported to be satisfied with their current medications (93%) and 88% of patients agreed or fully agreed with the statement "If my doctor said it was possible, I would be willing to stop one or more of my regular medicines". More than two thirds of participants were classified as having equal or higher than median medication adherence. **Table 2** shows patients' willingness to have medications deprescribed by medication adherence.

Table 1. Baseline characteristics, by willingness to have medications deprescribed

Variables	All participants (n=298)*	High willingness to have medications deprescribed (n=262)**	Lower willingness to have medications deprescribed (n=36)**
Female	133 (45)	115 (44)	18 (50)
Age (in years)	78 (74 – 83)	78 (73 – 83)	81 (77 – 84)
Education			
-Mandatory schooling or less	111 (38)	96 (37)	15 (42)
-Diploma at secondary school level or apprenticeship	139 (47)	126 (49)	13 (36)
-Higher education diploma	45 (15)	37 (14)	8 (22)
Living situation			
-In apartment/house without any external help	227 (76)	198 (76)	29 (81)
-In apartment/house with some external help	61 (20)	56 (21)	5 (14)
-In a residential aged care facility	10 (3)	8 (3)	2 (6)
Number of chronic conditions	7 (5 – 10)	7 (5 – 10)	7 (4 – 10)
Number of medications	7 (5 – 10)	7 (5 – 10)	7 (4 – 9)
Patient receiving informal care	11 (4)	8 (3)	3 (9)
Number of GP visits in the 6 months prior to trial enrolment	8 (5 – 14)	9 (5 – 15)	8 (6 – 13)
Number of specialists visits in the 6 months prior to trial enrolment	1 (0 – 2)	1 (0 – 2)	1 (1 – 2)
Hospital visits in the 6 months prior to trial enrolment	0 (0 – 1)	0 (0 – 0)	0 (0 – 0)
rPATD Q10. "I spend a lot of money on my medicines"			
Strongly agree	42 (14)	38 (15)	4 (11)
Agree	44 (15)	36 (14)	8 (22)
Unsure	26 (9)	22 (8)	4 (11)
Disagree	60 (20)	53 (20)	7 (19)
Strongly disagree	126 (42)	113 (43)	13 (36)
rPATD Q1. "Overall, I am satisfied with my current medicines"			
Strongly agree	215 (72)	184 (70)	31 (86)
Agree	64 (21)	61 (23)	3 (8)
Unsure	4 (1)	4 (2)	0 (0)
Disagree	11 (4)	10 (4)	1 (3)
Strongly disagree	4 (1)	3 (1)	1 (3)
Outcome			
Medication adherence score***	55 (55 – 56)	55 (55 – 56)	56 (55 – 56)

Categorical variables: frequencies and percentages are presented. Continuous outcomes: median and the interquartile range (IQR) are presented.

*Among the 298 patients, 146 patients were then randomized to the control group and 152 patients to the intervention group.

**Based on the rPATD question ""If my doctor said it was possible, I would be willing to stop one or more of my regular medicines". (Strongly agree/agree categorized as high willingness to have medications deprescribed; Unsure/disagree/ strongly disagree categorized as lower willingness to have medications deprescribed)

***Information on medication adherence was available for 276 patients at the 12-month follow-up. The score ranges from 0 to 56 points.

Table 2. Patients' willingness to have medications deprescribed

Variables	All participants (n=298)*
rPATD Q7. *"If my doctor said it was possible, I would be willing to stop one or more of my regular medicines"*	
Strongly agree/agree	262 (88)
Unsure/disagree/ strongly disagree	38 (12)
*Concerns about stopping factor score**	
	1.6 (1 - 2.4)
rPATD Q13. *"I would like to try stopping one of my medicines to see how I feel without it"*	
Strongly agree/agree	185 (62)
Unsure/disagree/ strongly disagree	113 (38)
rPATD Q14. *"I would like my doctor to reduce the dose of one or more of my medicines"*	
Strongly agree/agree	217 (73)
Unsure/disagree/ strongly disagree	81 (27)

Categorical variables: frequencies and percentages are presented. Continuous outcomes: median and the interquartile range (IQR) are presented.
*Among the 298 patients, 146 patients were then randomized to the control group and 152 patients to the intervention group.
**The concerns about stopping score was calculated based on 5 questions from the rPATD (Box 1). For factors, a higher total score indicates greater perceived concerns about stopping medicines (strongly agree = 5, agree = 4, unsure = 3, disagree = 2, strongly disagree = 1).[25]

The association between patients' willingness to have medications deprescribed and medication adherence from both the minimally and fully adjusted models are shown in **Table 3**. We did not find evidence for a statistically significant association between adherence and patients' reported willingness to have medications deprescribed as measured with the rPATD questions "If my doctor said it was possible, I would be willing to stop one or more of my regular medicines", "I would like my doctor to reduce the dose of one or more of my medicines", "I would like to try stopping one of my medicines to see how I feel without it" or the concerns about stopping score.

Table 3. Multivariate associations between patients' medication adherence and their willingness to have medications deprescribed

Name of the variable	Fully adjusted model (n=229)			Minimally adjusted model (n=271)		
	Coefficient	p-value	95% confidence interval	Coefficient	p-value	95% confidence interval
"If my doctor said it was possible, I would be willing to stop one or more of my regular medicines" (reference: agree/strongly agree)						
unsure/disagree/strongly disagree	0.10	0.819	-0.76 to 0.96	0.11	0.779	-0.66 to 0.88
Concerns about stopping score* (per 1-unit increase)	-0.07	0.736	-0.44 to 0.31	0.04	0.822	-0.28 to 0.35
"I would like to try stopping one of my medicines to see how I feel without it" (reference: agree/strongly agree)						
unsure/disagree/strongly disagree	0.22	0.447	-0.35 to 0.80	0.21	0.419	-0.29 to 0.71
"I would like my doctor to reduce the dose of one or more of my medicines" (reference: agree/strongly agree)						
unsure/disagree/strongly disagree	0.06	0.856	-0.57 to 0.69	0.04	0.894	-0.52 to 0.59

*The concerns about stopping score was calculated based on 5 questions from the rPATD (Box 1). For factors, a higher total score indicates greater perceived concerns about stopping medicines (strongly agree = 5, agree = 4, unsure = 3, disagree = 2, strongly disagree = 1).[25]

Multilevel linear regression models were performed. The fully adjusted model was adjusted for the clustering effect at the level of general practitioner, the group allocation, and for the following covariates: patient age, gender, educational status, living situation, number of chronic conditions, number of chronic medications, informal care received (yes/no), number of GP visits, number of specialist visits, number of hospitalizations, and rPATD questions "I spend a lot of money on my medicines" and "Overall, I am satisfied with my current medicines". The minimally adjusted model was adjusted for the clustering effect at the level of general practitioner, the group allocation, and for the following covariates: patient age, and gender.

Discussion

In this sub-study of a randomized clinical trial, we did not find evidence for an association between patients' reported willingness to have medications deprescribed and medication adherence. Participants in the sample generally reported a high level of medication adherence and self-reported willingness to have medications deprescribed.

Studies assessing adherence and self-reported willingness to deprescribe using the (r)PATD questionnaires have been conducted in Australia[31-33] (n=3) and Jordan[34] (n=1). Of the four studies, three different self-reported measurements of adherence were used: the Morisky Medication Adherence Score,[35] the Tool for Adherence Behaviour Screening (TABS),[36] and the Adherence Attitude Inventory (AAI).[37] No association was found between adherence and deprescribing outcomes in two of the Australian studies of deprescribing interventions (one used the PATD[31] and the other the rPATD[33]). A cross-sectional study conducted in Jordan[34]

(n=501) found that participants with high commitment to adherence (domain of the AAI) and high self-efficacy were less likely to be willing to deprescribe any of their medications. Their findings reflected a significant association between higher agreement with this rPATD deprescribing question and decreasing adherence. Similar to ours, this study also used the rPATD question: "I would like to try stopping one of my medicines to see how I feel without it" to assess deprescribing. However, our study was longitudinal and theirs cross-sectional, which must be considered when comparing the results.

There are different potential reasons for why we did not find evidence for an association between willingness to deprescribe and adherence. First, the methods used to measure willingness to deprescribe, and medication adherence may lack sensitivity or accuracy. Second, it can be hypothesized that a person with high self-efficacy and/or health literacy may be more likely to be both adherent and be willing to reduce or stop unnecessary medicines, recognizing both the benefits of adhering to medicines but also the potential harms of unnecessary or inappropriate medicines.

Our study was strengthened by its longitudinal design, which allows for a clear temporal distinction between patients' willingness to have medications deprescribed assessed at baseline and medication adherence at 12-month follow-up. In future research it would be interesting to examine the association between these two concepts in an opposite temporal order. Furthermore, it would be useful to study the association between those two concepts not only using self-reported questionnaires, but to use real-world adherence data (e.g., proportion days covered, use of electronic pill bottles) and data related to the implementation of specific deprescribing recommendations to determine if that would show the same results. Limitations were that participants who agreed to take part in the OPTICA trial may have been more motivated about their medications than their peers. The present analyses were a sub-study of the OPTICA trial, during which a medication review intervention was tested. Since the main trial findings did not show any differences in medication-related outcomes at the 12-month follow-up and since we adjusted the analyses for the group allocation, however, we think it is unlikely that the intervention has affected medication adherence at the 12-month

follow-up. Willingness to deprescribe was measured hypothetically meaning participants may feel differently about real-life deprescribing decisions. Adherence was assessed using a self-reported questionnaire, which may have led to an overestimation of adherence. It seems that the adherence measure we used (A14-scale) and the rPATD global question have a ceiling effect, therefore, misclassification bias cannot be excluded. Further, self-reported willingness to deprescribe and adherence may have been overestimated due to social desirability bias.

References

1. Malakouti SK, Javan-Noughabi J, Yousefzadeh N, et al. A Systematic Review of Potentially Inappropriate Medications Use and Related Costs Among the Elderly. *Value in Health Regional Issues*. 2021;25:172-179.

2. Redston MR, Hilmer SN, McLachlan AJ, Clough AJ, Gnjidic D. Prevalence of Potentially Inappropriate Medication Use in Older Inpatients with and without Cognitive Impairment: A Systematic Review. *Journal of Alzheimer's disease : JAD*. 2018;61(4):1639-1652. doi:10.3233/jad-170842

3. Ye L, Yang-Huang J, Franse CB, et al. Factors associated with polypharmacy and the high risk of medication-related problems among older community-dwelling adults in European countries: a longitudinal study. *BMC geriatrics*. 2022;22(1):1-13.

4. Howard RL, Avery AJ, Slavenburg S, et al. Which drugs cause preventable admissions to hospital? A systematic review. *British journal of clinical pharmacology*. 2007;63(2):136-147.

5. Mohammed MA, Moles RJ, Chen TF. Medication-related burden and patients' lived experience with medicine: a systematic review and metasynthesis of qualitative studies. *BMJ open*. 2016;6(2):e010035.

6. Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. *JAMA internal medicine*. 2015;175(5):827-834.

7. Bužančić I, Ortner Hadžiabdić M. Differences in Factors Influencing Deprescribing between Primary Care Providers: Cross-Sectional Study. *International Journal of Environmental Research and Public Health*. 2023;20(6):4957.

8. Glombiewski JA, Nestoriuc Y, Rief W, Glaesmer H, Braehler E. Medication adherence in the general population. *PLoS One*. 2012;7(12):e50537.

9. Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. *British journal of clinical pharmacology*. 2012;73(5):691-705.

10. Kullgren J, Solway E, Roberts S, et al. National Poll on Healthy Aging: Views on Medication Deprescribing Among Adults Age 50–80. 2023;

11. Gillespie RJ, Harrison L, Mullan J. Deprescribing medications for older adults in the primary care context: A mixed studies review. *Health science reports*. Jul 2018;1(7):e45. doi:10.1002/hsr2.45

12. Weir K, Nickel B, Naganathan V, et al. Decision-making preferences and deprescribing: perspectives of older adults and companions about their medicines. *The Journals of Gerontology: Series B*. 2018;73(7):e98-e107.

13. Vordenberg SE, Zikmund-Fisher BJ. Characteristics of older adults predict concern about stopping medications. *Journal of the American Pharmacists Association*. 2020;60(6):773-780.

14. Nguyen TMU, Caze AL, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. *British journal of clinical pharmacology*. 2014;77(3):427-445.

15.   Martin P, Tannenbaum C. A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial. *BMJ open*. 2017;7(4):e015959.

16.   Park HY, Seo SA, Yoo H, Lee K. Medication adherence and beliefs about medication in elderly patients living alone with chronic diseases. *Patient preference and adherence*. 2018:175-181.

17.   Jungo KT, Meier R, Valeri F, et al. Baseline characteristics and comparability of older multimorbid patients with polypharmacy and general practitioners participating in a randomized controlled primary care trial. *BMC family practice*. 2021;22(1):1-14.

18.   Jungo KT, Rozsnyai Z, Mantelli S, et al. 'Optimising PharmacoTherapy In the multimorbid elderly in primary CAre' (OPTICA) to improve medication appropriateness: study protocol of a cluster randomised controlled trial. *BMJ open*. 2019;9(9):e031080. doi:10.1136/bmjopen-2019-031080

19.   Jungo K, Ansorg A, Floriani C, et al. Optimizing Prescribing in Older Adults with Multimorbidity and Polypharmacy in Primary Care: A Cluster Randomized Clinical Trial (OPTICA Trial) (preprint) 2022

20.   Jungo KT, Ansorg AK, Floriani C, et al. Optimising prescribing in older adults with multimorbidity and polypharmacy in primary care (OPTICA): cluster randomised clinical trial. *Bmj*. May 24 2023;381:e074054. doi:10.1136/bmj-2022-074054

21.   Drenth-van Maanen AC, Leendertse AJ, Jansen PA, et al. The S ystematic T ool to R educe I nappropriate P rescribing (STRIP): Combining implicit and explicit prescribing tools to improve appropriate prescribing. *Journal of Evaluation in Clinical Practice*. 2018;24(2):317-322.

22.   Meulendijk MC, Spruit MR, Drenth-van Maanen A, et al. Computerized decision support improves medication review effectiveness: an experiment evaluating the STRIP assistant's usability. *Drugs & aging*. 2015;32(6):495-503.

23.   Meulendijk MC, Spruit MR, Willeboordse F, et al. Efficiency of clinical decision support systems improves with experience. *Journal of medical systems*. 2016;40(4):1-7.

24.   von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Journal of clinical epidemiology*. Apr 2008;61(4):344-9. doi:10.1016/j.jclinepi.2007.11.008

25.   Reeve E, Low L-F, Shakib S, Hilmer SN. Development and validation of the Revised Patients' Attitudes Towards Deprescribing (rPATD) Questionnaire: Versions for older adults and caregivers. *Drugs & Aging*. 2016;33(12):913-928. doi:http://dx.doi.org/10.1007/s40266-016-0410-1

26.   Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E. Consumer attitudes towards deprescribing: a systematic review and meta-analysis. *The Journals of Gerontology: Series A*. 2022;77(5):1020-1034.

27.   Jank S, Bertsche T, Schellberg D, Herzog W, Haefeli WE. The A14-scale: development and evaluation of a questionnaire for assessment of adherence and individual barriers. *Pharmacy world & science*. 2009;31(4):426-431.

28.   Kim NH, Look KA, Dague L, Winn AN. Financial burden and medication adherence among near-poor older adults in a pharmaceutical assistance program. *Research in Social and Administrative Pharmacy*. 2022/03/01/ 2022;18(3):2517-2523. doi:https://doi.org/10.1016/j.sapharm.2021.04.016

29.   Rogowski J, Lillard LA, Kington R. The Financial Burden of Prescription Drug Use Among Elderly Persons. *The Gerontologist*. 1997;37(4):475-482. doi:10.1093/geront/37.4.475

30.   Shikiar R, Rentz AM. Satisfaction with Medication: An Overview of Conceptual, Methodologic, and Regulatory Issues. *Value in Health*. 2004/03/01/ 2004;7(2):204-215. doi:https://doi.org/10.1111/j.1524-4733.2004.72252.x

31.   Cross AJ, George J, Woodward MC, Le VJ, Elliott RA. Deprescribing potentially inappropriate medications in memory clinic patients (DePIMM): a feasibility study. *Research in Social and Administrative Pharmacy*. 2020;16(10):1392-1397.

32.   Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S. People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. *Journal of the American Geriatrics Society*. 2013;61(9):1508-1514.

33. Kouladjian O'Donnell L, Gnjidic D, Sawan M, et al. Impact of the Goal-directed Medication Review Electronic Decision Support System on Drug Burden Index: A cluster-randomised clinical trial in primary care. *British journal of clinical pharmacology*. 2021;87(3):1499-1511.

34. Nusair MB, Khasawneh R, Al-azzam S, Al-Shuqairat T, Khair ZM, Arabyat R. Attitudes towards adherence and deprescribing among polypharmacy patients: a cross-sectional study. *Journal of Pharmaceutical Health Services Research*. 2022;13(3):180-190.

35. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. *Medical care*. 1986:67-74.

36. George J, Mackinnon A, Kong DC, Stewart K. Development and validation of the Beliefs and Behaviour Questionnaire (BBQ). *Patient education and counseling*. 2006;64(1-3):50-60.

37. Lewis SJ, Abell N. Development and evaluation of the Adherence Attitude Inventory. *Research on Social Work Practice*. 2002;12(1):107-123.